[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acs-acute-coronary-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acs-acute-coronary-syndrome":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,40,72,112,139,169,197,229,256,281],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100630370","a-clinical-study-on-the-effect-of-cardiopulmonary-function-and-quality-of-life-in-patients-with-acute-coronary-syndrome-complicated-by-heart-failure-by-lying-sitting-standing-sequential-baduanjin-100630370",false,"NCT07486791","A Clinical Study on the Effect of Cardiopulmonary Function and Quality of Life in Patients With Acute Coronary Syndrome Complicated by Heart Failure by \"Lying-Sitting-Standing\" Sequential Baduanjin","Inclusion Criteria:\n\n* Patients meeting the diagnostic criteria for ACS (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction)\n* Complicated by heart failure during hospitalization\n* Age ≤ 85 years\n* Muscle strength ≥ grade 3\n* No history of mental illness, conscious and able to cooperate independently with this study\n* Voluntarily participate in this study and sign the informed consent form\n\nExclusion Criteria:\n\n* Patients with persistent heart failure symptoms or NYHA functional class IV despite optimal pharmacological therapy;\n* Patients with contraindications to cardiac rehabilitation, such as uncontrolled hypertension, uncontrolled arrhythmias, or hemodynamic instability;\n* Patients with untreated structural heart disease, such as heart failure caused by valvular heart disease or congenital heart disease;\n* Patients in the acute phase of various diseases, such as severe infection, deep vein thrombosis, or severe hepatic or renal failure;\n* Patients with disabilities, bone or joint diseases, or neurological disorders that preclude participation in Baduanjin exercises;\n* Patients with a life expectancy of less than one year;\n* Patients currently participating in other clinical trials.","ALL","85 Years",{"count":18,"type":19},65,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study investigates the effects of a sequential \"lying-sitting-standing\" Baduanjin intervention on patients with acute coronary syndrome complicated by heart failure. By evaluating cardiopulmonary function and quality of life through indicators such as echocardiography, NT-proBNP, 6MWT, NYHA classification, and SF-36, we aim to compare its efficacy with conventional treatment. The objective is to provide new insights for early cardiac rehabilitation strategies in patients with acute coronary syndrome complicated by heart failure",[25,26],"ACS (Acute Coronary Syndrome)","HF - Heart Failure","RECRUITING","2026-04-29",{"date":30,"type":31},"2026-05-05","ACTUAL",{"date":33,"type":31},"2026-03-10",{"date":35,"type":19},"2027-06-01",{"name":37,"class":38},"Xiling Qi","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":20,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":39},"100619978","phase-4-ccta-evaluation-of-sglt2i-related-pericoronary-fat-changes-in-non-diabetic-acs-patients-without-hf-100619978","NCT07351643","CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF","Assessment of the Effects of SGLT2 Inhibitors on Pericoronary Fat in Non-diabetic ACS Patients Without Heart Failure Using CCTA","DAPA-PCAT","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Diagnosis of acute coronary syndrome (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina)\n3. Undergoing percutaneous coronary intervention (PCI)\n4. Presence of multivessel coronary artery disease with at least one non-culprit vessel not undergoing revascularization (for CCTA follow-up assessment)\n5. Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Prior or current diagnosis of diabetes mellitus\n2. Prior or current diagnosis of chronic heart failure\n3. Treatment with any SGLT2 inhibitor within 4 weeks prior to enrollment\n4. Severe hepatic impairment\n5. History of recurrent urogenital infections\n6. Known allergy or intolerance to SGLT2 inhibitors\n7. Pregnancy or breastfeeding\n8. Systolic blood pressure \\\u003C90 mmHg and\u002For diastolic blood pressure \\\u003C60 mmHg\n9. Severe chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n10. Current participation in another interventional clinical trial\n11. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for enrollment","18 Years",{"count":50,"type":19},110,[52],"PHASE4","The goal of this clinical trial is to learn if dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), can reduce coronary artery inflammation in people with acute coronary syndrome (ACS) who do not have diabetes or heart failure.\n\nCoronary inflammation will be measured using the fat attenuation index (FAI), a marker derived from coronary CT angiography (CCTA) that quantifies inflammation in the fat tissue surrounding heart arteries.\n\nThe main questions it aims to answer are:\n\n* Does dapagliflozin lower coronary artery inflammation as measured by FAI?\n* Does dapagliflozin slow the progression of coronary plaques?\n\nResearchers will compare participants who take dapagliflozin 10 mg daily plus standard therapy to those who receive standard therapy alone for 6 months.\n\nParticipants will:\n\n* Undergo percutaneous coronary intervention (PCI) for ACS\n* Have a baseline CCTA scan at 1 month after PCI, at which point they will be randomly assigned to receive dapagliflozin or standard care alone\n* Have a follow-up CCTA scan at 6 months after randomization\n* Have blood tests at the time of PCI, at randomization, and at 6 months after randomization\n* Receive follow-up phone calls at 3 and 6 months after randomization",[25,55],"SGLT2 Inhibitors",[57,58,59,60,61],"Fat attenuation index","SGLT2 inhibitors","Pericoronary adipose tissue","Residual inflammatory risk","Coronary CT angiography","NOT_YET_RECRUITING","2026-01-12",{"date":65,"type":31},"2026-01-20",{"date":67,"type":19},"2026-02-25",{"date":69,"type":19},"2026-12-30",{"name":71,"class":38},"Shenyang Northern Hospital",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":39},"100613307","for-patients-with-myocardial-infarction-and-multiple-vessel-testing-if-ultrasound-ufr-can-guide-all-needed-treatment-in-one-procedure-avoiding-a-return-hospital-visit-for-a-second-operation-100613307","NCT07264881","For Patients With Myocardial Infarction and Multiple Vessel: Testing if Ultrasound (UFR) Can Guide All Needed Treatment in One Procedure, Avoiding a Return Hospital Visit for a Second Operation.","A Prospective, Longitudinal, Multi-modal Study Evaluating the Utility of Acute Phase UFR (IVUS-FFR) to Predict Functional Significance in the Stable Phase for Patients With Acute Coronary Syndrome (ACS)","ACT-EVOLVE","Inclusion Criteria:\n\n* Age \\>18 years, any sex.\n* The participant is able to understand the study procedures and provides voluntary written informed consent.\n* Diagnosed with Acute Coronary Syndrome (ACS) and meets the criteria for one of the two pre-specified cohorts:\n* STEMI Cohort: Symptom onset \\\u003C 12 hours with ECG findings of ST-segment elevation myocardial infarction.\n* High-Risk NSTEMI Cohort: Meets at least one of the following: GRACE score \\> 140, dynamic ECG changes (ST-T), or significant Troponin elevation.\n* Has undergone successful emergency PCI of the Culprit Vessel (CV), with post-PCI TIMI flow Grade 3.\n* Coronary angiography confirms Multi-vessel Disease (MVD), defined as: at least one Non-Culprit Vessel (NCV) with a moderate stenosis (visual diameter stenosis 50-90%).\n* The target NCV (50-90% stenosis) is deemed by the investigator to be anatomically suitable for IVUS and pressure-wire assessment.\n* The participant agrees and is confirmed to be willing and able to strictly adhere to the protocol and complete all required invasive procedures, CMR scans, and follow-ups at the four timepoints (T0, T-CMR, T1, T2).\n\nExclusion Criteria:\n\n* Presence of cardiogenic shock on presentation, or persistent hemodynamic instability despite successful PCI of the culprit vessel.\n* Known severe allergy to iodinated contrast media or gadolinium-based contrast agents (used for CMR).\n* Female participants who are pregnant, breastfeeding, or planning pregnancy within the 1-year study period.Unprotected left main coronary artery disease (stenosis \\\u003C50%) requiring intervention.\n* Prior history of Coronary Artery Bypass Grafting (CABG) surgery.The target NCV has received prior PCI (e.g., existing stent) or surgical revascularization.\n* The target NCV is a Chronic Total Occlusion (CTO).\n* Severe renal insufficiency (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m²) or currently undergoing chronic dialysis.\n* Standard contraindications to CMR examination (e.g., claustrophobia, non-MRI-compatible metallic implants\u002Fpacemakers).\n* Known presence of a severe non-cardiac comorbidity with an expected lifespan of \\\u003C 12 months (e.g., advanced malignancy).\n* Known severe hematological disease (e.g., severe anemia, active bleeding, thrombocytopenia \\\u003C 70 x 10⁹\u002FL) rendering the participant unsuitable for multiple invasive procedures.\n* Inability to provide informed consent or comply with the complex longitudinal follow-up protocol due to psychiatric, cognitive, or other reasons.\n* Currently participating in another interventional (drug or device) clinical study.\n* Any other condition which, in the investigator's opinion, makes the participant unsuitable for enrollment (e.g., severe valvular heart disease, cardiomyopathy).",{"count":81,"type":19},200,"OBSERVATIONAL","Brief Summary The Purpose of the Study : The purpose of this study is to find a safe and reliable \"one-stop\" solution for treating heart attack patients who have multiple blocked arteries. Currently, doctors face a dilemma: Testing these other blockages during the heart attack procedure is often unreliable.\n\nThe most accurate method requires asking the patient to return 30 days later for a second invasive procedure, which is a significant burden.\n\nThe Study's Hypothesis : We are testing a new tool called UFR, which uses ultrasound images to measure blockages. Our hypothesis (or \"educated guess\") is that this new UFR tool is not affected by the body's stress during a heart attack and can provide a true, reliable measurement right away.\n\nThe Question the Study is Trying to Answer ： The main question this study is trying to answer is: Can the new \"one-stop\" UFR tool, used during the initial heart attack procedure, accurately predict which blockages are truly serious... thereby eliminating the need for patients to return for a second procedure 30 days later? Researchers will also follow 200 patients for one year, using advanced scans (like UFR, standard tests, and MRI), to better understand how the heart and arteries heal and change over time.",[85,86,25,87],"Microvascular Obstruction (MVO)","Multivessel Coronary Artery Disease","ST Elevation Myocardial Infarction (STEMI)",[89,90,91,92,93,94,95,96,97,98,99,100,101,102],"Acute Coronary Syndrome","Fractional Flow Reserve,","Intravascular Ultrasound","Virtual Fractional Flow Reserve","Functional Drift","Coronary Microvascular Dysfunction","Index of Microcirculatory Resistance","Non-Culprit Vessel","ST Elevation Myocardial Infarction","Non-ST Elevation Myocardial Infarction","Cardiac Magnetic Resonance","Microvascular Obstruction","Staged Revascularization","Computational Fluid Dynamics","2025-11-24",{"date":105,"type":31},"2025-12-04",{"date":107,"type":19},"2025-12-02",{"date":109,"type":19},"2028-06-22",{"name":111,"class":38},"Beijing Anzhen Hospital",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":120,"targetDuration":122,"studyType":82,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":39},"100610765","registry-of-coronary-disease-outcomes-revascularizing-with-drug-coated-balloons-100610765","NCT07231835","Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons","RECORD-DCB: Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons","RECORD-DCB","Inclusion Criteria:\n\n* Patients undergoing PCI with the Protégé paclitaxel-eluting DCB\n* Age ≥ 18 years\n* Presence of a de novo lesion or in-stent restenosis in a native coronary artery or a in a bypass graft and suitable for PCI\n* Reference vessel diameter between 2.0 - 4.5 mm\n* Patient suitable for dual antiplatelet therapy (DAPT)\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Allergy to paclitaxel",{"count":121,"type":19},3000,"5 Years","The primary aim of this registry is to systematically collect and analyze real-world data on all patients undergoing PCI with the Protégé paclitaxel-eluting DCB to evaluate procedural outcomes, long-term efficacy, and safety across various clinical indications. This registry aims to assess the clinical effectiveness of DCB therapy across diverse patient populations, including those with stable coronary artery disease (CAD) and acute coronary syndromes (ACS), as well as various lesion subsets, encompassing (but not limited to) in-stent restenosis (ISR), de novo coronary lesions, small vessel disease, bifurcation and calcified lesions, coronary bypass graft lesions, and patients at high risk of bleeding. Additionally, the study aims to identify predictors of success, complications, and optimal treatment strategies to further refine the use of DCBs.",[125,126,127,128,25,129],"Percutaneous Coronary Intervention (PCI)","Drug Coated Balloon","Paclitaxel","CAD - Coronary Artery Disease","Stable Coronary Artery Disease (CAD), Myocardial Infarction","2025-11-14",{"date":132,"type":31},"2025-11-17",{"date":134,"type":31},"2025-11-11",{"date":136,"type":19},"2034-09-30",{"name":138,"class":38},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":16,"enrollmentInfo":147,"targetDuration":149,"studyType":82,"phases":4,"briefSummary":150,"conditions":151,"keywords":157,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":167,"locationsCount":39},"100594996","tirana-acs-a-prospective-registry-study-for-the-targeted-investigation-of-residual-inflammation-after-non-st-st-elevation-acute-coronary-syndrome-100594996","NCT07026708","TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST\u002F ST Elevation Acute Coronary Syndrome","Target Investigation of Residual Inflammation After Non-ST\u002F ST Elevation Acute Coronary Syndrome - TIRANA (ACS) Prospective REGISTRY","TIRANA (ACS)","Inclusion Criteria:\n\n\\- All patients (undergoing PCI, aged 18-85 years) presenting to the cardiology department or\u002Fand the cardiology intensive care unit with a diagnosis of ACS\n\nExclusion Criteria:\n\n* Patients presenting to the cardiology department or\u002Fand the cardiology intensive care unit with diagnoses other than ACS and\u002For UA. Patients who died before undergoing PCI and those who did not provide a contact number.",{"count":148,"type":19},1600,"2 Years","This prospective observational study aims to evaluate the prognostic significance of the neutrophil-to-lymphocyte ratio (NLR) as a predictor of mortality in patients following an episode of Acute Coronary Syndrome (ACS). Despite advancements in interventional cardiology and medical therapy, mortality remains significant in post-ACS patients, and early risk stratification is essential for optimizing outcomes.\n\nRecent studies have suggested that systemic inflammatory markers, such as NLR, are associated with adverse cardiovascular events. It is an easily obtainable and cost-effective laboratory parameter derived from a routine complete blood count. However, its value as an independent predictor of mortality post-ACS has not yet been fully established in our population.\n\nThe study will include patients aged, admitted with a confirmed diagnosis of ACS (STEMI or Non-STEMI) and treated with percutaneous coronary intervention (PCI). NLR values will be measured from the first blood draw upon hospital admission, 24 and 48 hours post PCI. Patients will be followed up for up to 6 months after discharge through telephone interviews .\n\nFirst, primary outcomes of the study will be the association between NLR values and mortality (all cause mortality and cardiovascular mortality), MACE (MACE was defined as the composite of all-cause mortality, cardiac death, unplanned revascularization, non-fatal myocardial infarction that was attributable and not related to stent failure or unplanned revascularization not related to stent failure) within 6 months post-ACS.\n\nSecondary outcomes will include:\n\n1. Differences in mean NLR between STEMI and NSTEMI patients.\n2. Association between elevated NLR and the presence of multivessel coronary artery disease on angiography.\n3. Correlation of NLR with other biomarkers, including the platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), high-density lipoprotein (HDL) cholesterol, and maximum troponin levels (as an indicator of myocardial infarction size)\n\nThis study aims to contribute to the identification of easily accessible and cost-efficient biomarkers that can aid clinicians in early risk stratification of ACS survivors. A strong correlation between high NLR values and increased post-discharge mortality would suggest that inflammation plays a key role in patient prognosis and could potentially influence post-ACS management strategies.",[25,152,153,154,155,156],"Myocardial Infarction (MI)","Myocardial Inflammation","Inflammation Biomarkers","NSTEMI - Non-ST Segment Elevation MI","STEMI",[158,159,160,89],"Residual inflammation","Myocardial infarction","Percutaneous Coronary Intervention","2025-09-27",{"date":163,"type":31},"2025-09-30",{"date":165,"type":31},"2024-11-01",{"date":35,"type":19},{"name":168,"class":38},"University Hospital Centre Mother Teresa",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":15,"minAge":176,"maxAge":4,"enrollmentInfo":177,"targetDuration":179,"studyType":82,"phases":4,"briefSummary":180,"conditions":181,"keywords":185,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":4},"100607570","prospective-observational-cohort-study-on-impact-of-frailty-on-risk-prediction-treatment-strategies-and-short-term-outcomes-in-patients-with-acute-coronary-syndrome-100607570","NCT07190274","Prospective Observational Cohort Study on Impact of Frailty on Risk Prediction, Treatment Strategies, and Short-Term Outcomes in Patients With Acute Coronary Syndrome","Impact of Frailty on Risk Prediction, Treatment Strategies, and Short-Term Outcomes in Patients With Acute Coronary Syndrome","Inclusion Criteria:\n\n* Elderly: Age ≥65 years .\n* STEMI\u002FNSTEMI (ESC\u002FACC criteria)\n* Presentation \\\u003C24h of symptom onset\n\nExclusion Criteria:\n\n* Terminal illness (life expectancy \\\u003C1 month)\n* Severe dementia precluding assessment\n* Declined consent","65 Years",{"count":178,"type":19},645,"1 Month","we aim :\n\n* To evaluate how frailty influences acute management decisions (invasive vs conservative strategy) in ACS patients and whether it independently affects short-term outcomes.\n* To determine whether adding frailty assessment to existing ACS risk prediction models improves the prediction of 30-day mortality and major adverse cardiovascular events (MACE) in elderly ACS patients.",[182,25,183,184],"Frailty","MACE","GRACE Score",[186,187],"frailty","ACS","2025-09-22",{"date":190,"type":31},"2025-09-24",{"date":192,"type":19},"2025-12-01",{"date":194,"type":19},"2028-06-01",{"name":196,"class":38},"Assiut University",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":204,"targetDuration":206,"studyType":82,"phases":4,"briefSummary":207,"conditions":208,"keywords":217,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":39},"100600398","cardiac-rehabilitation-cohort-at-the-medicine-campus-davos-to-investigate-recovery-100600398","NCT07096973","Cardiac REhabilitation COhort at the Medicine Campus DaVos to invEstigate Recovery","RECOVER","Inclusion Criteria:\n\n* Patients undergoing CR at the HGK\n* Written informed consent\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents, the interview, or questionnaires interview without translation\n* Physical or psychological incapability to participate in the study",{"count":205,"type":19},10000,"10 Years","The RECOVER study, titled Cardiac Rehabilitation Cohort at the Medicine Campus Davos for Exploration of Recovery, is a prospective, non-interventional, monocentric cohort study conducted at the Hochgebirgsklinik Davos. The study is sponsored by Medicine Campus Davos AG and the Kühne Foundation, with an estimated start date in July 2025 and planned completion by December 2034, with the possibility of extension.\n\nThe principal investigator of the study is PD Dr. David Niederseer from Hochgebirgsklinik Davos, who also represents the study. The research team includes co-investigators such as Prof. Dr. Stefan Blankenberg and Prof. Dr. Andreas Ziegler from Cardio-CARE, Medicine Campus Davos, as well as Dr. Jan Vontobel from Hochgebirgsklinik Davos.\n\nThe study will enroll patients referred to Hochgebirgsklinik Davos for cardiac rehabilitation who provide informed consent. Cardiac rehabilitation is an evidence-based therapy for patients with heart disease, including those who have undergone cardiac procedures or surgeries.\n\nThe primary objectives are to evaluate baseline patient characteristics, rehabilitation strategies, predictors of recovery, and clinical outcomes during and after rehabilitation. To support this, a detailed database and biobank will be established to allow for comprehensive phenotyping, extensive clinical assessments, and long-term follow-up.\n\nRECOVER seeks to gain translational insights into how patient-specific factors - such as genetics, plasma, digital and clinical biomarkers, and comorbidities - influence long-term clinical outcomes. The goal is to identify modifiable risk factors to optimize individualized therapeutic approaches in cardiac rehabilitation.",[209,210,211,25,212,213,214,215,216],"Cardiac Rehabilitation","Heart Failure","Cardiac Arrest (CA)","CABG","Valve Anomalies","LVAD (Left Ventricular Assist Device)","Heart Transplantation","Arrhythmia",[218,219],"cardiovascular diseases","cardiac rehabilitation","2025-09-11",{"date":222,"type":31},"2025-09-17",{"date":224,"type":31},"2025-08-05",{"date":226,"type":19},"2040-08-05",{"name":228,"class":38},"Hochgebirgsklinik Davos",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":237,"enrollmentInfo":238,"targetDuration":149,"studyType":82,"phases":4,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":4},"100602834","clinical-features-and-long-term-prognosis-in-young-patients-with-acute-myocardial-infarction-100602834","NCT07128667","Clinical Features and Long-Term Prognosis in Young Patients With Acute Myocardial Infarction","A Prospective Cohort Study on Clinical Characteristics, Risk Factors, and Long-Term Outcomes in Young Patients With Acute Myocardial Infarction","AMI-Youth","Inclusion Criteria:\n\n1. Age between 18 and 45 years (inclusive of 18 and 45 years);\n2. Meeting the diagnostic criteria for acute myocardial infarction (including both ST-elevation myocardial infarction and non-ST-elevation myocardial infarction);\n3. Presenting for medical attention within 24 hours of symptom onset;\n4. The subject (or their legal representative) is willing and able to sign the informed consent form (for the prospective follow-up portion);\n5. Life expectancy greater than 1 year.\n\nExclusion Criteria:\n\n* (1) History of prior old myocardial infarction, severe valvular heart disease, or heart failure; (2) Pregnancy or lactation; (3) Mental disorders or other conditions that prevent cooperation with treatment; (4) Concomitant severe infection, inflammatory or immunological biomarker changes unrelated to AMI, trauma, or recent major surgery.","45 Years",{"count":81,"type":19},"The incidence of acute myocardial infarction (AMI) in young patients is on the rise, placing a heavy health and economic burden on individuals, families, and society. The clinical phenotype and pathophysiological mechanisms of AMI in this population exhibit significant heterogeneity compared to elderly patients, and existing risk assessment tools have limited applicability in this specific group. The core problem this study aims to address is: how to accurately identify specific risk factors in young AMI patients and build an effective risk prediction model to prevent and optimize clinical diagnosis and treatment.\n\nThis study will adopt a prospective cohort design to collect multi-dimensional clinical data from young AMI patients. It will systematically analyze their clinical characteristics, risk factors, and coronary lesion status to comprehensively map the clinical, risk factor, and pathophysiological diversity of young AMI patients. Secondly, it will delve into identifying specific risk factors that influence the onset, progression, and long-term prognosis of young AMI. Thirdly, it will combine machine learning algorithms to develop a risk prediction model for young AMI, performing internal validation in the prospective cohort and external validation in the MIMIC-IV database. Simultaneously, it will explore novel biomarkers associated with disease onset and progression. The key outcomes of this study are to establish a high-quality clinical database of young AMI patients, design a risk prediction model for young AMI based on the study results, and produce high-level academic publications.",[25,241],"Young Adults",[243,244,245,246],"acute myocardial infarction","young adults","prognosis","risk factors","2025-08-14",{"date":249,"type":31},"2025-08-19",{"date":251,"type":19},"2025-09-01",{"date":253,"type":19},"2028-12-31",{"name":255,"class":38},"China-Japan Friendship Hospital",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":176,"enrollmentInfo":262,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":264,"conditions":265,"keywords":268,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":4},"100574322","evaluation-of-remnant-cholesterol-levels-and-monocyte-to-hdl-cholesterol-ratio-as-predictors-of-coronary-artery-disease-severity-in-patients-with-acute-coronary-syndrome-100574322","NCT06757777","Evaluation of Remnant Cholesterol Levels and Monocyte-to-HDL-cholesterol Ratio as Predictors of Coronary Artery Disease Severity in Patients With Acute Coronary Syndrome","Inclusion Criteria:\n\n* Patients with acute coronary syndrome presented to ER of Assiut university hospital scheduled for primary PCI and able to provide informed consent.\n\nExclusion Criteria:\n\n* Patients on previous statin therapy.\n* Patients with severe renal dysfunction (creatinine clearance \\\u003C30 mL\u002Fmin) or other contraindications to PCI.\n* Patients with missed data or who couldn't be followed up",{"count":263,"type":19},54,"1. Evaluation of serum level of remnant cholesterol and monocyte\u002FHDL ratio as predictors of severity of coronary artery disease in patients with acute coronary syndrome.\n2. Evaluate predictive value of remnant cholesterol serum level and monocyte\u002FHDL ratio to detect in-hospital worse clinical outcomes and 45 days major adverse cardiac events (MACE) after acute coronary syndrome.",[89,25,266,156,267],"Monocyte to HDL Cholesterol Ratio","Non STEMI",[269,270,156,271,272],"Acs","Acute coronary syndrome","NON STEMI","Monocyte\u002FHDL Ratio","2025-02-07",{"date":275,"type":31},"2025-02-11",{"date":277,"type":19},"2025-02-08",{"date":279,"type":19},"2026-03-08",{"name":196,"class":38},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":20,"phases":291,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":39},"100574437","phase-4-impact-of-cyp2c19-genotype-guided-approach-in-antiplatelet-therapy-on-platelet-reactivity-index-among-coronary-artery-disease-cad-patients-100574437","NCT06759272","Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients","Pharmacogenomic Markers of Clopidogrel Resistance in Malaysian CAD Patients: Clinical Efficacy and Economic Evaluation of CYP2C19 Genotype-Guided Therapy","Inclusion Criteria:\n\n* Males or females\n* Aged between 18 to 80 years old\n* Patients presents with stable CAD or acute coronary syndrome (ACS)\n* Eligible for percutaneous coronary intervention (PCI)\n* Willing to provide DNA sample via blood drawn for genotyping and platelet reactivity assessment\n* Willing and able to provide informed written consent\n\nExclusion Criteria:\n\n* Primary PCI or rescue PCI\n* Any urgent\u002Femergent coronary angiography procedure that would not allow for genetic testing to be performed before PCI\n* Failure of index PCI\n* Patient or physician refusal to enroll in the study\n* Patient with known CYP2C19 genotype prior to randomization\n* Planned revascularization of any vessel within 30 days post-index procedure and\u002For of the target vessel(s) within 12 months post-procedure\n* Anticipated discontinuation of clopidogrel or ticagrelor within the 12 months follow up period (e.g. for elective surgery)\n* History of ischaemic or haemorrhagic stroke\n* History of allergies to aspirin, ticagrelor, or clopidogrel\n* Suffering from HIV or any blood transmitted disease.\n* Considered at high risk of bleeding\\*\n* Stage 5 chronic kidney disease (CKD) based on the National Kidney Foundation, Kidney disease quality outcome initiative (KDQOI) definition (Levey et al., 2005), or those who were on haemodialysis\n* Pre-existing liver cirrhosis\n* Pregnant women at any stage of gestation\n* Patient is receiving immunosuppressive therapy or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematous, etc.)\n* Patient is receiving chronic anticoagulation therapy (i.e. vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor)\n* Concomitant use of simvastatin\u002Flovastatin \\>40 mg qd\n* Concomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine)\n* Non-cardiac condition limiting life expectancy to less than a year, per judgement of physician","80 Years",{"count":290,"type":19},120,[52],"The goal of this clinical trial is to learn if the pilot intervention of CYP2C19 genotype-guided antiplatelet therapy works to reduce the occurrence of cardiovascular events after Percutaneous Coronary Intervention (PCI) done in coronary artery disease patients. It will also learn about the comparison between clopidogrel and ticagrelor.\n\nThe main questions it aims to answer are:\n\nTo compare the impact of CYP2C19 genotype-guided antiplatelet therapy, universal use of clopidogrel and ticagrelor treatment on platelet reactivity.\n\nTo compare the impact of CYP2C19 genotype-guided antiplatelet therapy, universal use of clopidogrel and ticagrelor treatment on the risk of major adverse cardiovascular events (MACE) among newly recruited stable CAD patients.\n\nParticipants will:\n\nTake drug clopidogrel or ticagrelor, based on the random group allocation every day for 1 month. One group of patients will undergone CYP2C19 genetic test for genotype-guided antiplatelet therapy, whether clopidogrel or ticagrelor.\n\nVisit the clinic post 30 days of PCI for follow-ups and platelet function tests.",[294,25,295],"Coronary Arterial Disease (CAD)","SCAD",[297],"CYP2C19 genotype-guided antiplatelet therapy","2025-01-04",{"date":300,"type":31},"2025-01-07",{"date":302,"type":19},"2025-02",{"date":304,"type":19},"2026-02",{"name":306,"class":38},"Nur Hafizah Annezah binti Utuh"]